Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc. MRNA, +1.57% said in a news release on Monday that both of its new COVID-19 boosters produced a better antibody response against the BA.4 and BA.5 variants in a Phase 2/3 clinical than the company's original booster. Moderna has two bivalent boosters, one of which is authorized for use in the U.S. That shot, mRNA-1273.222, produced a "superior neutralizing antibody response" against BA.4 and BA.5 in about 500 clinical-trial participants who had already been vaccinated and boosted.

Moderna says its new COVID-19 boosters work against BA.5, BQ.1.1

Moderna Inc said on Monday its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.

Moderna's Omicron shots shows better immune response than original COVID vaccine

In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273 Results build upon data recently published in the New England Journal of Medicine that confirmed superiority of the Company's BA.1 bivalent vaccine, mRNA-1273.214, neutralizing titers against multiple Omicron variants compared to a booster dose of mRNA-1273 Both of the Company's updated bivalent boosters (mRNA-1273.214 and mRNA-1273.222) showed neutralizing titers against BQ.1.1, an emerging threat globally, in an exploratory analysis Safety and tolerability of mRNA-1273.214 and mRNA-1273.222 were similar to a booster dose of mRNA-1273 and adverse events were generally lower than the second dose of the primary series CAMBRIDGE, MA / ACCESSWIRE / November 14, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that both of Moderna's bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared to a booster dose of mRNA-1273, the Company's prototype vaccine, against Omicron (BA.4/BA.5) in Phase 2/3 clinical trials. Both bivalent vaccines also met non-inferiority immunogenicity criteria to the original strain.

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

The company said its new shot generated more antibodies against Omicron than its original booster.

Moderna's New Covid-19 Booster Produced Strong Immune Response in Study

Pfizer

Zoetis

These stocks are down, but they're definitely not out.

3 Beaten-Down Stocks to Buy Right Now

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China , Nov. 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) today announced that Nona Biosciences, a subsidiary wholly owned by the Company, had entered into a license and collaboration agreement with ModernaTX, Inc. (NASDAQ: MRNA), a global biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines.

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

Moderna continues development of at least 15 vaccine programs targeting emerging or neglected infectious diseases by 2025 as part of global health program Moderna is committed to clinical trial diversity to ensure health equity Moderna working to achieve net-zero carbon emissions globally by 2030 in Scopes 1 and 2 and is committed to defining science-based carbon reduction targets in Scope 3 As of September 2022, 50% of Moderna employees are women, including 41% of leaders at the Vice President level or above Virtual ESG Day to be held today at 9:00 a.m. ET CAMBRIDGE, MA / ACCESSWIRE / November 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted progress on its environmental, social and governance (ESG) strategy presented at the Company's first ESG Day.

Moderna Shares Environmental, Social and Governance Highlights at First ESG Day

Moderna shares are heading for a 35% decline this year.

Ready to Sell Moderna? Check Out This Chart First

Ally Financial

Empire State Realty Trust

Nextdoor

Simon Property Group

These companies clearly think their shares are good values.

5 Companies Buying Back Their Stock Aggressively in This Bear Market

Tesla

Select analysts believe these widely held growth stocks could plummet from their current price.

2 Nasdaq 100 Stocks That Could Plunge as Much as 88%, According to Wall Street

Bank of America

Disney

MercadoLibre

Atlassian

Investing in these five stocks could be a great way to start putting your money to work in the stock market.

5 Cheap Stocks Beginning Investors Can Buy Right Now

One valuation model could hint at a further decline for the vaccine stock.

Why Moderna Stock Could Still Be More Than 50% Overvalued

AbbVie

Bristol-Myers

BioNTech SE

Johnson & Johnson

Eli Lilly

With the pandemic years in the rearview mirror, some of the best pharma stocks should continue to perform well. For one, by 2030, the pharma industry could be worth nearly $1.6 trillion, according to Acumen Research and Consulting.

The 7 Best Pharma Stocks to Buy Now

The market was pleased with the biotech's latest regulatory win.

Why Moderna Stock Jumped on Monday

It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.

The Big Pharma Giants Are Down

Is Moderna a Bad-News Buy?

Is the next phase of revenue growth just ahead?

3 Things You Need to Know About Moderna's Post-Pandemic Revenue

Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money.

Did Vaccine Stocks Just Get Their Last Boost?

mRNA-1273.222 targets BA.4/BA.5 Omicron subvariants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which targets the Omicron BA.1 subvariant CAMBRIDGE, MA / ACCESSWIRE / November 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has authorized the use of its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/BA.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.

Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Activision Blizzard

CoStar Group

First Solar

Garmin

Incyte

Regeneron Pharmaceuticals

Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way.

7 Cash-Rich Stocks to Buy for Peace of Mind

Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters. The post This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters appeared first on Investor's Business Daily.

This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters

Is Moderna stock a buy or a sell after cutting its 2022 outlook for Covid vaccines just as Pfizer, BioNTech unveil promising booster news? The post Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?

Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?

This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills.

Moderna's Earnings Collapsed. Time to Sell?

COVID-19 vaccine maker Moderna's shares fell on Thursday following the release of the company's third-quarter earnings, which showed a decline in revenue.

Moderna stock tumbles after quarterly earnings show revenue declines

Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.

News for Moderna Stock (MRNA)